Dermatology

Creatine supplementation in hemodialysis: A futile exercise?

Intradialytic creatine supplementation in hemodialysis patients showed feasibility and tolerability but lacked evidence of meaningful clinical improvement in a pilot study.

The hidden dangers in chemical hair relaxers your patients need to know

Chemical hair relaxers are linked to increased risks of uterine fibroids, endometriosis, and certain cancers. Clinicians should counsel patients on these potential dangers.

Lebrikizumab maintains atopic dermatitis remission for months off-therapy

Lebrikizumab monotherapy sustained deep remission in atopic dermatitis patients for up to 38 weeks after treatment cessation.

Does dupilumab increase lymphoma risk in eczema patients?

Dupilumab, a common eczema treatment, has raised questions about its potential link to lymphoma. Data suggests no increased risk, but vigilance remains key.

Peptide Therapies: Decoding Evidence from Topicals to Longevity

Peptide therapies show varied efficacy across indications, from established dermatological uses to investigational longevity applications. Clinicians must scrutinise the evidence for each specific peptide.

Dermatomyositis Guidelines Identify Cancer Risk

New guidelines provide a structured approach for identifying dermatomyositis patients at high risk for cancer, streamlining screening protocols for European clinicians.

Litfulo Label Strengthened With New Alopecia Areata Safety Warnings

The European Medicines Agency has updated the product information for Litfulo, adding new warnings regarding serious adverse events for patients with alopecia areata.

FDA Rejects Galderma's RelabotulinumtoxinA for Second Time

Galderma's relabotulinumtoxinA received a second Complete Response Letter from the FDA, delaying its entry into the aesthetic market.

CAR T-Cell Therapy Nears Approval for Refractory Skin Diseases

CAR T-cell therapy shows promise for severe, refractory autoimmune skin conditions, with regulatory filings anticipated for specific indications.